Coronavirus Disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus, which is a contagious respiratory virus causing atypical pneumonia COVID-19 in adult and children with Severe Acute Respiratory Syndrome (SARS). The SARS-CoV-2 genome also encodes four structural (S, E, M and N) and up to six accessory (3a, 6, 7a, 7b, 8, and 9b) proteins. The spike protein (S) is further divided into 2 subunits, S1 and S2 that mediate host cell attachment and invasion. Anti-SARS-CoV-2 Monoclonal Antibodies (mAbs) that target the spike protein have been shown to yield clinical benefits in treating SARS-CoV-2 infection. This article represents a clinical case of a 59-year-old man with Coronavirus Disease (COVID-19) and intracerebral haemorrhage, who was treated with the use of monoclonal antibodies bamlanivimab and etesevimab. Equally, it presents a review of these drugs’ application for COVID-19 treatment in adults
and children

Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus, which affects both children and adults. Although most cases of COVID-19 in children have a mild course, sometimes the disease is severe. Multisystem inflammatory syndrome in children (MIS-C) is a rare complication of COVID-19, characterized by pronounced cardiovascular, gastrointestinal, and skin-mucosal signs and symptoms that, in particular, may meet the criteria for atypical or typical Kawasaki disease (KD). This article represents a clinical case of a 13-year-old boy with an atypical course of SARS-CoV-2-
Induced Kawasaki-Like Multisystem Hyperinflammatory Syndrome, who was treated with intravenous immunoglobulin, corticosteroids, and aspirin. Equally, it presents a thorough description of carrying out a differential diagnosis between MIS-C and Kawasaki disease and a review of the application of drugs needed for MIS-C treatment, the main goal of which is to ensure the best protection against CA aneurysms and avoid long-term sequelae.